Novo Nordisk is also addressing this target with CagriSema, a combination of long-acting amylin analogue cagrilintide and GLP-1 agonist semaglutide – which disappointed in its first phase 3 ...
Last December, Novo Nordisk revealed phase 3 results for cagrisema, a combination of semaglutide and an amylin analog called cagrilintide. Sadly, it doesn't look like cagrisema works any better ...
It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback